A growing momentum for earlier treatment of psoriasis has the potential to improve outcomes with oral therapies and biologics ...

Broad-based skin cancer screening may strain healthcare resources and lead to overdiagnosis, but it may also help catch more ...

Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...

Other pharmaceutical and health care companies recently announced layoffs — including Bayer, Siemens, RWJBarnabas Health and ...

The radioligand agent is now approved for use before chemotherapy in patients who have been treated with an androgen receptor ...

When Novartis bought kidney disease biotech Chinook Therapeutics in 2023 for $3.2 billion upfront, the deal included a ...

The U.S. Food and Drug Administration (FDA) on Wednesday granted accelerated approval for Novartis AG’s (NYSE:NVS) Vanrafia ...

Destampasidis requested media coverage of the trial - Maria Marangelis, the former protected witness "Ekaterini Kelesi", is ...

Novartis AG's plan to sell its 70.68% stake in Novartis India faces challenges due to market volatility impacting valuation.

Novartis ( NYSE: NVS) said on Thursday that it received US FDA's accelerated approval for Vanrafia as a treatment for adults ...

Approval was based on results from the Phase III ALIGN study, which demonstrated a significant reduction in proteinuria at 36 ...

Novartis’ Vanrafia (atrasentan) has been granted accelerated approval by the US Food and Drug Administration (FDA) to treat ...